NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
Other share classesNAMS
Insider trades, last 90 days
1 buy · 3 sells
- Bought $226.5K
- Sold $6.59M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
9
- 0 vs. Q1 2026
- Total value $28.09M
Superinvestors holding NAMSW
0
- None of the superinvestors held NAMSW at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by NAMSW insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 20264:30 PM ET | Sep 14, 2026 | Davidson Michael H.Chief Executive Officer | PPurchaseOrdinary Shares | +10K | $22.65 | +$226.5K | 792.92K | +1.3% | SEC |
| Sep 9, 20264:30 PM ET | Sep 4, 2026 | Smither John WDirector | SSaleOrdinary Shares | −1.6K | $25.32 | −$40.51K | 8.76K | −15.4% | SEC |
| Aug 25, 20264:30 PM ET | Aug 24, 2026 | Kastelein Johannes Jacob PieterChief Scientific Officer | SSaleOrdinary Shares | −125K | $26.91 | −$3.36M | 69.3K | −64.3% | SEC10b5-1 |
| Jul 22, 20264:05 PM ET | Jul 20, 2026 | Kooij Louise FrederikaChief Accounting Officer | SSaleOrdinary Shares | −105K | $30.3396 | −$3.19M | 24.35K | −81.2% | SEC10b5-1 |
| Jun 24, 2026 | Jun 22, 2026 | Kooij Louise FrederikaChief Accounting Officer | SSaleOrdinary Shares | −40K | $30.204 | −$1.21M | 24.35K | −62.2% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in NAMSW at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 500,333 | $10.69M | 0.23% | 00.0% | Unchanged |
| RA CAPITAL MANAGEMENT, L.P. | 333,333 | $7.12M | 0.06% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 245,000 | $5.34M | 0.26% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 99,999 | $2.14M | 0.13% | 00.0% | Unchanged |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 92,787 | $1.98M | 0.02% | 00.0% | Unchanged |